The Stargate Initiative, spearheaded by several tech giants, has raised alarm in the most paranoid parts of the MAGA movement ...

Yulan Xiong, associate professor of neuroscience at UConn Health, and her team have discovered one more piece of the puzzle ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Doretha Clemons, Ph.D., MBA, PMP, has been a corporate IT executive and professor for 34 years. She is an adjunct professor at Connecticut State Colleges & Universities, Maryville University, and ...

With more than 1,800 laptops tested, these are the best laptops for drawing and digital art if you're an artist. Why you can trust TechRadar We spend hours testing every product or service we ...

Despite a tough 2024, MRNA's pipeline reprioritization and $9 billion cash reserve position it for potential blockbuster products and revenue growth by 2028. Financial discipline has reduced cash ...

What about an mRNA vaccine for H5N1? There isn't one yet, but several companies—including Moderna, Pfizer and GlaxoSmithKline (in collaboration with CureVac)—are working on such a shot.

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...

Instead they end in a conserved stem–loop that interacts with stem–loop binding protein (SLBP), a factor involved in several steps of histone mRNA metabolism: pre-mRNA processing, translation ...

Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, ...

Encourage students to share the stories behind their drawings, which in turn will lead to good communication between all the students. Display the finished artwork in the classroom or school ...

The mRNA cancer vaccine mRNA-4157, developed with Merck (MRK) might have the most promising upside with biopharma awaiting a key Phase 2 interim readout for the melanoma treatment in Q4 2025/H1 2026.